Effect of an intravitreal injection of bevacizumab on the expression of VEGF and CD34 in the retina of diabetic rats

Clinical and Experimental Ophthalmology

Volumn 38, Issue 9, 2010, Pages 875-884

  Ma, Jin ^a   Zhu, TiePei ^a   Tang, Xiajin ^a   Ye, Panpan ^a   Zhang, Zhen ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bevacizumab; Diabetes; Prevention; Retinal angiogenesis

Indexed keywords

BEVACIZUMAB; CD34 ANTIBODY; SODIUM CHLORIDE; STREPTOZOCIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EFFECT; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; RETINA CAPILLARY; RETINA NEOVASCULARIZATION; STREPTOZOCIN DIABETES; TRANSMISSION ELECTRON MICROSCOPY; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD34; BIOLOGICAL MARKERS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; ENDOTHELIAL CELLS; IMMUNOHISTOCHEMISTRY; INTRAVITREAL INJECTIONS; MALE; MICROSCOPY, ELECTRON; RATS; RATS, WISTAR; RETINA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78650146186     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2010.02370.x     Document Type: Article

References (44)

1. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-34.
2. Amy D'Orazio DL. Adding a humanized antibody to vascular endothelial growth factor (bevacizumab, Avastin) to chemotherapy improves survival in metastatic colorectal cancer. Clin Colorectal Cancer 2003; 8: 85-8.
3. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-5.
4. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
5. Yang JC. Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res 2004; 10: (18 Pt 2): 6367S-70S.
6. Michels S, Rosenfeld PJ, Puliafito CA et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112: 1035-47.
7. Nguyen QD, Shah S, Tatlipinar S et al. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 2005; 89: 1368-70.
8. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005; 36: 336-9.
9. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006; 26: 275-8.
10. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26: 352-4.
11. Nakagawa T, Kosugi T, Haneda M et al. Abnormal angiogenesis in diabetic nephropathy. Diabetes 2009; 58: 1471-8.
12. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 442-7.
13. Adamis AP, Miller JW, Bernal MT et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445-50.
14. Tolentino MJ, McLeod DS, Taomoto M et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 2002; 133: 373-85.
15. Tolentino MJ, Miller JW, Gragoudas ES et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996; 103: 1820-8.
16. Miller JW, Adamis AP, Aiello P. Vascular endothelial growth factor in ocular neovascularization and proliferative retinopathy. Diabetes Metab Rev 1997; 13: 37-50.
17. Inhibition VEGF. Study in Ocular Neovascularization(VISION) Clinical trial group. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006; 113: 992-1001.
18. Avery RL. Intravitreal bevacizumb (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-72.
19. Soheilian M, Ramezani A, Bijanzadeh B et al. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 2007; 27: 1187-95.
20. Minnella AM, Savastano CM, Ziccardi L et al. Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy. Acta Ophthalmol 2008; 86: 683-7.
21. Shahar J, Avery RL, Heilweil G et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006; 26: 262-9.
22. Civin C, Strauss LC, Brovall C et al. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 1984; 133: 157-65.
23. Fina L, Molgaard HV, Robertson D et al. Expression of the CD34 gene in vascular endothelial cells. Blood 1990; 75: 2417-26.
24. Barth PJ, Westhoff CC. CD34+ fibrocytes: morphology, histogenesis and function. Curr. Stem Cell Res Ther 2007; 2: 221-7.
25. Cui S, Hano H, Sakata A et al. Enhanced CD34 expression of sinusoid-like vascular endothelial cells in hepatocellular carcinoma. Pathol Int 1996; 46: 751-6.
26. Jankowski RJ, Deasy BM, Cao B et al. The role of CD34 expression and cellular fusion in the regeneration capacity of myogenic progenitor cells. J Cell Sci 2002; 115 (Pt 22): 4361-74.
27. Joussen AM, Poulaki V, Tsujikawa A et al. Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol 2002; 160: 1683-93.
28. Battegay EJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 1995; 73: 333-46.
29. Ferrara N, Damico L, Shams N et al. Developmemt of Ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006; 26: 859-70.
30. Avery RL, Pieramici DJ, Rabena MD et al. Intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration. Ophthalmology 2006; 113: 363-72.
31. Yu L, Wu X, Cheng Z et al. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci 2008; 49: 522-7.
32. Ferrara N, Hillan KJ, Gerber HP et al. Discovery and evelopment of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
33. Bock F, Onderka J, Dietrich T et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007; 48: 2545-52.
34. Manzano RP, Peyman GA, Khan P et al. Inhibition of experimental corneal neovascularization by bevacizumab (Avastin). Br J Ophthalmol 2007; 91: 804-7.
35. Klettner A, Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci 2008; 49: 4523-7.
36. Ameri H, Chader GJ, Kim J et al. The effects of intravitreous bevacizumab on retinal neovascular membrane and normal capillaries in rabbits. Invest Ophthalmol Vis Sci 2007; 48: 5708-15.
37. Lassota N, Prause JU, Scherfig E et al. Clinical and histological findings after intravitreal injection of bevacizumab (Avastin(R)) in a porcine model of choroidal neovascularization. Acta Ophthalmol 2010; 88: 300-8. [Epub ahead of print.
38. Heiduschka P, Fietz H, Hofmeister S et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007; 48: 2814-23.
39. Al-Dhibi H, Khan AO. Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema. J AAPOS 2009; 13: 400-2.
40. Wu Z, Sadda SR. Effects on the contralateral eye after intravitreal bevacizumab and ranibizumab injections: a case report. Ann Acad Med Singapore 2008; 37: 591-3.
41. Avery RL, Pearlman J, Pieramici DJ et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 1695-705.
42. Bakri SJ, Snyder MR, Reid JM et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114: 855-9.
43. Velez-Montoya R, Fromow-Guerra J, Burgos O et al. The effect of unilateral intravitreal bevacizumab (Avastin), in the treatment of diffuse bilateral diabetic macular edema: A pilot study. Retina 2009; 29: 20-6.
44. Miyake T, Sawada O, Kakinoki M et al. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci 2010; 51: 1606-8. [Epub ahead of print.